[CAS NO. ] Sarilumab

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS

Catalog

HY-P9916

Brand

MCE

CAS

DESCRIPTION

Overview

MDL	-
Molecular Weight	-
Molecular Formula	-
SMILES	[Sarilumab]

For research use only. We do not sell to patients.

Summary

Sarilumab (Anti-Human IL6Rα, Human Antibody) is a human immunoglobulin G1 monoclonal antibody. Sarilumab, a interleukin-6 (IL-6) receptor antagonist, binds to the IL-6 receptor with high affinity and inhibits cis and trans signaling by IL-6 , resulting in reduced inflammation. Sarilumab can be used for the research of Rheumatoid arthritis ^[1] ^[2] .

IC50 & Target

IL-6

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT01217814	Sanofi\|Regeneron Pharmaceuticals	Rheumatoid Arthritis	November 2010	Phase 2
NCT03600805	Sanofi\|Regeneron Pharmaceuticals	Giant Cell Arteritis	November 20, 2018	Phase 3
NCT03535402	Gaylis, Norman B., M.D.	Rheumatoid Arthritis	June 1, 2018	Phase 3
NCT03414502	University of Nebraska	Rheumatoid Arthritis	August 2007	Phase 3
NCT02121210	Sanofi\|Regeneron Pharmaceuticals	Rheumatoid Arthritis	June 2014	Phase 3
NCT02776735	Sanofi\|Regeneron Pharmaceuticals	Juvenile Idiopathic Arthritis	September 6, 2016	Phase 2
NCT02332590	Sanofi\|Regeneron Pharmaceuticals	Rheumatoid Arthritis	January 28, 2015	Phase 3
NCT04357808	Maria del Rosario Garcia de Vicuña Pinedo\|Instituto de Investigación Sanitaria Hospital Universitario de la Princesa\|Fundación de Investigación Biomédica - Hospital Universitario de La Princesa	Covid-19	April 13, 2020	Phase 2
NCT02373202	Sanofi\|Regeneron Pharmaceuticals	Rheumatoid Arthritis	February 2015	Phase 3
NCT01850680	Sanofi\|Regeneron Pharmaceuticals	Rheumatoid Arthritis	April 2013	Phase 1
NCT02404558	Sanofi\|Regeneron Pharmaceuticals	Rheumatoid Arthritis	May 2015	Phase 1
NCT04350216	Instituto de Investigación Marqués de Valdecilla	Rheumatoid Arthritis\|Atherosclerosis	April 30, 2020	Phase 4
NCT05535738	John Harris\|University of Massachusetts, Worcester	Skin Inflammation\|Allergic Contact Dermatitis	September 15, 2022	Phase 2\|Phase 3
NCT02735707	UMC Utrecht\|Australian and New Zealand Intensive Care Research Centre\|Medical Research Institute of New Zealand\|Unity Health\|Berry Consultants\|Global Coalition for Adaptive Research\|University of Pittsburgh Medical Center\|Intensive Care National Audit & Research Centre\|St. Marianna University School of Medicine\|National Intensive Care Surveillance MORU	Community-acquired Pneumonia, Influenza, COVID-19	April 11, 2016	Phase 3
NCT01061723	Sanofi\|Regeneron Pharmaceuticals	Ankylosing Spondylitis	February 2010	Phase 2
NCT04315298	Regeneron Pharmaceuticals\|Sanofi	COVID-19	March 18, 2020	Phase 2\|Phase 3
NCT04386239	ASST Fatebenefratelli Sacco	COVID19	January 1, 2021	Early Phase 1
NCT04333706	University of Florida\|National Cancer Institute (NCI)	Breast\|Metastatic\|Triple Negative\|Cancer\|Disseminated Tumor Cell	September 26, 2020	Phase 1\|Phase 2
NCT02017639	Sanofi\|Regeneron Pharmaceuticals	Rheumatoid Arthritis	January 2014	Phase 1
NCT04359901	Westyn Branch-Elliman\|VA Boston Healthcare System	COVID	April 10, 2020	Phase 2
NCT01764997	Sanofi\|Regeneron Pharmaceuticals	Rheumatoid Arthritis	April 2013	Phase 3
NCT02293902	Sanofi\|Regeneron Pharmaceuticals	Rheumatoid Arthritis	November 2014	Phase 3
NCT03770273	National Institute of Allergy and Infectious Diseases (NIAID)\|National Institutes of Health Clinical Center (CC)	Indolent Systemic Mastocytosis	June 19, 2019	Phase 2
NCT04842981	University of Southern Denmark\|Odense University Hospital\|Hospital of South West Jutland\|King Christian X´Hospital for Rheumatic Diseases\|Sygehus Lillebaelt\|Odense Patient Data Explorative Network	Arthritis, Rheumatoid\|Interaction	May 25, 2021	Phase 1\|Phase 2
NCT04357860	Maimónides Biomedical Research Institute of Córdoba\|Consejería de Salud y Familias - Junta de Andalucía\|Red Andaluza de Ensayos Clínicos en Enfermedades Infecciosas (Red ANCRAID)	SARS-CoV 2\|SARS	April 28, 2020	Phase 2
NCT03378219	Sanofi\|Regeneron Pharmaceuticals	Rheumatoid Arthritis -Exposure During Pregnancy	May 18, 2018
NCT04661527	Clinica Universidad de Navarra, Universidad de Navarra\|Sanofi\|Hospital Universitario Infanta Leonor	COVID-19 Drug Treatment	April 22, 2020	Phase 2
NCT01900431	Sanofi	Uveitis	October 2013	Phase 2
NCT04134728	GlaxoSmithKline\|Iqvia Pty Ltd	Arthritis, Rheumatoid	October 31, 2019	Phase 3
NCT03679845	Massachusetts General Hospital\|Regeneron Pharmaceuticals	Morphea, Plaque Form	September 1, 2019	Phase 1\|Phase 2
NCT04008069	Stanford University	Sarcoidosis	September 3, 2019	Phase 2
NCT02097524	Regeneron Pharmaceuticals\|Sanofi	Rheumatoid Arthritis	March 2014	Phase 1
NCT04341870	Assistance Publique - Hôpitaux de Paris	COVID19\|SARS-CoV-2 Infection	April 11, 2020	Phase 2\|Phase 3
NCT02057250	Sanofi\|Regeneron Pharmaceuticals	RA	March 2014	Phase 3
NCT01768572	Sanofi\|Regeneron Pharmaceuticals	Rheumatoid Arthritis	March 2013	Phase 3
NCT01061736	Sanofi\|Regeneron Pharmaceuticals	Rheumatoid Arthritis	March 2010	Phase 2\|Phase 3
NCT01118728	Sanofi\|Regeneron Pharmaceuticals	Ankylosing Spondylitis	June 2010	Phase 2
NCT02991469	Sanofi\|Regeneron Pharmaceuticals	Juvenile Idiopathic Arthritis	August 9, 2018	Phase 2
NCT03449758	Sanofi\|Regeneron Pharmaceuticals	Rheumatoid Arthritis	March 5, 2018	Phase 4
NCT03600818	Sanofi\|Regeneron Pharmaceuticals	Polymyalgia Rheumatica	October 9, 2018	Phase 3
NCT04324073	Assistance Publique - Hôpitaux de Paris	Corona Virus Infection	March 27, 2020	Phase 2\|Phase 3
NCT04327388	Sanofi\|Regeneron Pharmaceuticals	Corona Virus Infection	March 28, 2020	Phase 3
NCT01709578	Sanofi\|Regeneron Pharmaceuticals	Rheumatoid Arthritis	October 2012	Phase 3
NCT05428007	NYU Langone Health	Melanoma\|Unresectable Melanoma	December 1, 2022	Phase 2

Shipping

Shipping with dry ice.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.